Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/132091
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nielsen, S. | - |
dc.contributor.author | Sabioni, P. | - |
dc.contributor.author | Gowing, L. | - |
dc.contributor.author | Le Foll, B. | - |
dc.contributor.editor | Nadar, M.A. | - |
dc.contributor.editor | Hurd, Y.L. | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Substance Use Disorders: From Etiology to Treatment, 2020 / Nadar, M.A., Hurd, Y.L. (ed./s), vol.258, Ch.13, pp.355-372 | - |
dc.identifier.isbn | 3030336786 | - |
dc.identifier.isbn | 9783030336783 | - |
dc.identifier.uri | https://hdl.handle.net/2440/132091 | - |
dc.description.abstract | This chapter reviews pharmacotherapies that have been trialled for cannabis dependence, identifying those that warrant further research and those of little or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agonists warrant further research. For the FAAH inhibitor PF-04457845, oxytocin, varenicline and gabapentin, although there is a signal to indicate further research is warranted, these medications do not yet have sufficient evidence to support clinical use, and larger, longer-term trials are needed in representative treatment-seeking populations. Special populations that warrant consideration are those with cannabis dependence and concurrent mental health conditions and those that develop dependence through therapeutic use. | - |
dc.description.statementofresponsibility | Suzanne Nielsen, Pamela Sabioni, Linda Gowing, and Bernard Le Foll | - |
dc.language.iso | en | - |
dc.publisher | Springer | - |
dc.relation.ispartofseries | Handbook of Experimental Pharmacology; 258 | - |
dc.rights | © Springer Nature Switzerland AG 2019 | - |
dc.source.uri | https://link.springer.com/book/10.1007/978-3-030-33679-0 | - |
dc.subject | Cannabis; Cannabis dependence; Cannabis use disorder; Pharmacotherapy; Treatment | - |
dc.title | Pharmacotherapies for cannabis use disorders: Clinical challenges and promising therapeutic agents | - |
dc.type | Book chapter | - |
dc.identifier.doi | 10.1007/164_2019_258 | - |
dc.publisher.place | Cham, Switzerland | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Gowing, L. [0000-0002-9124-4056] | - |
Appears in Collections: | Aurora harvest 4 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.